Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens
Prokopios Magiatis, Evangelos Dadiotis, Romanos Konstantinos Antonopoulos, K Ioannidis, V Mitsis, E Melliou, Zacharoula Gonou‐zagou
Planta Medica December 1, 2022 DOI: 10.1055/s-0042-1759062 via OpenAlex
Summary
AI-generated from the abstractThe genus Psilocybe contains over two hundred species of mushroom-forming fungi that produce the secondary metabolite psilocybin, which is a prodrug converted in the body to the active metabolite psilocin. Psilocybin is currently being used in clinical trials for treating Major Depressive Disorder, existential distress in terminally ill patients, and Alcohol Use Disorder, creating a need to investigate and quantitate these substances.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Prodrug Secondary metabolite Biology Stereochemistry |
| Citations | 1 |
| Key finding | Psilocybin, a prodrug of psilocin produced by Psilocybe fungi, is being used in clinical trials for Major Depressive Disorder, existential distress in terminally ill patients, and Alcohol Use Disorder. |
Abstract
The genus Psilocybe of Basidiomycota includes more than two hundred species of mushroom-forming fungi, which are widely known for the production of the secondary metabolite psilocybin, a prodrug of its in vivo dephosphorylated active metabolite psilocin [1]. Psilocybin is being currently used in numerous clinical trials including the treatment of Major Depressive Disorder (MDD) [2], existential distress of terminally ill patients [3] and Alcohol Use Disorder (AUD) [4], creating the need of investigating and quantitating these substances.